Fri Aug 4 16:55:14 2006
Robust hepatitis C virus infection in vitro
Zhong J, Gastaminza P, Cheng GF, et al.
PNAS 102 (26): 9294-9299 JUN 28 2005
and citing papers
stopwords, and 2-character and smaller words are excluded, Word count: 611, All words count: 910
Grand TLCS: 121, Grand TGCS: 212View: Overview | Sorted by number of publications (Pubs). |
Page 1 of 2: [ 1 2 ]
# | Word | Pubs | TLCS | TGCS
|
---|
1 | HEPATITIS | 58 | 120 | 210
|
2 | VIRUS | 54 | 115 | 186
|
3 | REPLICATION | 10 | 10 | 22
|
4 | CELL | 9 | 7 | 8
|
5 | INFECTIOUS | 8 | 7 | 9
|
6 | RNA | 8 | 0 | 2
|
7 | CELLS | 7 | 4 | 4
|
8 | ANTIVIRAL | 6 | 7 | 42
|
9 | ENTRY | 6 | 5 | 5
|
10 | HCV | 6 | 2 | 3
|
11 | HUMAN | 6 | 4 | 4
|
12 | REPLICON | 6 | 1 | 1
|
13 | CULTURE | 5 | 5 | 6
|
14 | VIRAL | 5 | 1 | 2
|
15 | CHARACTERIZATION | 4 | 0 | 0
|
16 | INFECTION | 4 | 72 | 72
|
17 | INHIBITOR | 4 | 0 | 1
|
18 | INTERFERON | 4 | 4 | 16
|
19 | PRODUCTION | 4 | 4 | 5
|
20 | PROTEIN | 4 | 7 | 42
|
21 | ACTIVATION | 3 | 4 | 4
|
22 | ANALYSIS | 3 | 2 | 4
|
23 | EFFECT | 3 | 0 | 1
|
24 | EXPRESSION | 3 | 0 | 1
|
25 | GENOTYPE | 3 | 1 | 2
|
26 | HEPATOMA | 3 | 4 | 4
|
27 | HOST | 3 | 6 | 22
|
28 | INHIBITS | 3 | 2 | 3
|
29 | PROTEINS | 3 | 1 | 1
|
30 | SUBGENOMIC | 3 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
31 | SYSTEM | 3 | 5 | 5
|
32 | THERAPEUTIC | 3 | 1 | 1
|
33 | THERAPY | 3 | 0 | 0
|
34 | VITRO | 3 | 73 | 73
|
35 | ACTIVITY | 2 | 0 | 0
|
36 | ASSAY | 2 | 0 | 0
|
37 | BINDING | 2 | 0 | 0
|
38 | BIOLOGICAL | 2 | 0 | 1
|
39 | DEVELOPMENT | 2 | 0 | 1
|
40 | DIFFERENT | 2 | 0 | 0
|
41 | DISTINCT | 2 | 0 | 0
|
42 | EFFECTS | 2 | 1 | 1
|
43 | FUNCTION | 2 | 8 | 15
|
44 | FUNCTIONAL | 2 | 1 | 2
|
45 | FUSION | 2 | 3 | 3
|
46 | GENOME | 2 | 8 | 15
|
47 | GLYCOPROTEINS | 2 | 4 | 5
|
48 | INDUCED | 2 | 0 | 0
|
49 | INHIBITION | 2 | 0 | 1
|
50 | INHIBITORS | 2 | 0 | 0
|
51 | INNATE | 2 | 0 | 2
|
52 | INTERACTION | 2 | 0 | 0
|
53 | INTERACTIONS | 2 | 3 | 9
|
54 | INTRACELLULAR | 2 | 3 | 19
|
55 | LIPOPROTEIN | 2 | 1 | 1
|
56 | LIPOPROTEINS | 2 | 0 | 0
|
57 | LIVER | 2 | 0 | 0
|
58 | LUCIFERASE | 2 | 0 | 0
|
59 | MECHANISM | 2 | 3 | 16
|
60 | MEDIATE | 2 | 3 | 3
|
# | Word | Pubs | TLCS | TGCS
|
---|
61 | MOLECULAR | 2 | 1 | 1
|
62 | NOVEL | 2 | 0 | 1
|
63 | PARTICLES | 2 | 0 | 0
|
64 | POLYMERASE | 2 | 0 | 1
|
65 | POTENT | 2 | 0 | 0
|
66 | POTENTIAL | 2 | 0 | 0
|
67 | PROTEASE | 2 | 0 | 0
|
68 | QUANTITATIVE | 2 | 2 | 4
|
69 | RECEPTOR | 2 | 0 | 0
|
70 | RECEPTORS | 2 | 0 | 0
|
71 | REPORTER | 2 | 0 | 0
|
72 | REQUIRES | 2 | 1 | 2
|
73 | RESEARCH | 2 | 0 | 0
|
74 | RESPONSES | 2 | 0 | 0
|
75 | RIBAVIRIN | 2 | 4 | 16
|
76 | ROBUST | 2 | 73 | 73
|
77 | SCAVENGER | 2 | 0 | 0
|
78 | STRAIN | 2 | 1 | 1
|
79 | TARGETS | 2 | 0 | 1
|
80 | TISSUE | 2 | 1 | 2
|
81 | USING | 2 | 0 | 0
|
82 | VIVO | 2 | 2 | 2
|
83 | ACHILLES | 1 | 0 | 0
|
84 | ACTION | 1 | 3 | 15
|
85 | ACTIVE | 1 | 0 | 0
|
86 | ACTIVITIES | 1 | 0 | 0
|
87 | ADAPTIVE | 1 | 0 | 0
|
88 | ADAPTOR | 1 | 7 | 41
|
89 | ADVANCES | 1 | 0 | 1
|
90 | ALPHA | 1 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
91 | ALPHA-GLUCOSIDASE | 1 | 0 | 0
|
92 | ANALYSES | 1 | 0 | 0
|
93 | ANTI-HCV | 1 | 0 | 0
|
94 | ANTI-HEPATITIS | 1 | 1 | 1
|
95 | ANTIBODIES | 1 | 0 | 0
|
96 | ANTIBODY | 1 | 0 | 0
|
97 | APOB-CONTAINING | 1 | 0 | 0
|
98 | APOLIPOPROTEIN | 1 | 0 | 0
|
99 | APOPTOSIS | 1 | 1 | 2
|
100 | APPLIED | 1 | 0 | 0
|
101 | APPROACH | 1 | 0 | 0
|
102 | ASSEMBLY | 1 | 1 | 2
|
103 | BASIC | 1 | 0 | 0
|
104 | BILIARY | 1 | 0 | 0
|
105 | BREAKTHROUGH | 1 | 0 | 0
|
106 | BROADLY | 1 | 0 | 0
|
107 | CAPTURING | 1 | 0 | 0
|
108 | CARCINOMA | 1 | 0 | 0
|
109 | CARDIF | 1 | 7 | 41
|
110 | CDNA-TRANSFECTED | 1 | 2 | 2
|
111 | CELL-BASED | 1 | 0 | 1
|
112 | CELL-CELL | 1 | 0 | 0
|
113 | CHIMERAS | 1 | 0 | 0
|
114 | CIRCLE | 1 | 1 | 2
|
115 | CLA | 1 | 0 | 0
|
116 | CLATHRIN-MEDIATED | 1 | 0 | 0
|
117 | CLEAVAGE | 1 | 0 | 0
|
118 | CLINICAL | 1 | 0 | 1
|
119 | COMBINATION | 1 | 0 | 0
|
120 | COMPLEX | 1 | 2 | 4
|
# | Word | Pubs | TLCS | TGCS
|
---|
121 | CONCOMITANT | 1 | 1 | 2
|
122 | CONFLUENCE-BASED | 1 | 0 | 1
|
123 | CONSTRUCTION | 1 | 0 | 0
|
124 | CONTROL | 1 | 1 | 1
|
125 | CORE-RNA | 1 | 0 | 0
|
126 | COUNTERS | 1 | 0 | 2
|
127 | CULTURE-GROWN | 1 | 2 | 2
|
128 | CULTURED | 1 | 1 | 1
|
129 | CULTURES | 1 | 0 | 0
|
130 | CYCLOSPORIN | 1 | 0 | 0
|
131 | CYCLOSPORINE | 1 | 0 | 0
|
132 | CYTOSKELETON | 1 | 0 | 0
|
133 | DC-SIGN | 1 | 0 | 0
|
134 | DC-SIGNR | 1 | 0 | 0
|
135 | DEBIO | 1 | 0 | 0
|
136 | DEFENCE | 1 | 3 | 19
|
137 | DEFINED | 1 | 0 | 0
|
138 | DELETION | 1 | 0 | 0
|
139 | DENSITY | 1 | 0 | 0
|
140 | DEPENDS | 1 | 0 | 0
|
141 | DETECTION | 1 | 1 | 1
|
142 | DIFFERENCE | 1 | 3 | 3
|
143 | DIHYDROXY-4-CARBOXYPYRIMIDINES | 1 | 0 | 0
|
144 | DIMERIZATION | 1 | 0 | 0
|
145 | DIRECT | 1 | 0 | 0
|
146 | DISCOVERY | 1 | 0 | 0
|
147 | DISORDERS | 1 | 0 | 0
|
148 | DISPENSABLE | 1 | 0 | 0
|
149 | DIVERSE | 1 | 0 | 0
|
150 | DOMAINS | 1 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
151 | DRUG | 1 | 0 | 1
|
152 | DSRNA-INDUCED | 1 | 0 | 0
|
153 | EARLY | 1 | 0 | 0
|
154 | EFFICIENT | 1 | 3 | 3
|
155 | EFFICIENTLY | 1 | 1 | 1
|
156 | EMPIRICISM | 1 | 0 | 0
|
157 | ENDOCYTOSIS | 1 | 0 | 0
|
158 | ENDOTHELIUM | 1 | 0 | 0
|
159 | ENGAGEMENT | 1 | 0 | 0
|
160 | ENHANCES | 1 | 0 | 0
|
161 | ENVELOPE | 1 | 0 | 0
|
162 | EPITOPE | 1 | 0 | 0
|
163 | ERADICATION | 1 | 0 | 0
|
164 | ESCAPE | 1 | 0 | 0
|
165 | EVASION | 1 | 3 | 19
|
166 | EXHIBITS | 1 | 0 | 0
|
167 | FACE | 1 | 0 | 1
|
168 | FEATURES | 1 | 1 | 1
|
169 | FULL | 1 | 1 | 2
|
170 | FULLY | 1 | 0 | 0
|
171 | FUNCTIONS | 1 | 0 | 0
|
172 | FUTURE | 1 | 0 | 1
|
173 | GENERATED | 1 | 0 | 0
|
174 | GENERATION | 1 | 0 | 0
|
175 | GROW | 1 | 0 | 0
|
176 | GROWTH | 1 | 0 | 1
|
177 | HAIRPIN | 1 | 0 | 0
|
178 | HEEL | 1 | 0 | 0
|
179 | HELICASE | 1 | 0 | 0
|
180 | HELICASES | 1 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
181 | HEPATOCELLULAR | 1 | 0 | 0
|
182 | HEPATOCYTES | 1 | 0 | 0
|
183 | HIGH | 1 | 0 | 0
|
184 | HIGHLY | 1 | 0 | 1
|
185 | HOME-GROWN | 1 | 0 | 0
|
186 | HORSE | 1 | 0 | 0
|
187 | HUTCHINSON | 1 | 1 | 1
|
188 | IDENTIFY | 1 | 0 | 0
|
189 | IFN-BETA | 1 | 1 | 1
|
190 | IMMORTALIZED | 1 | 0 | 0
|
191 | IMMUNE | 1 | 0 | 0
|
192 | IMMUNITY | 1 | 0 | 2
|
193 | INCORPORATION | 1 | 1 | 2
|
194 | INDEPENDENT | 1 | 0 | 0
|
195 | INHIBIT | 1 | 0 | 0
|
196 | INSERTION | 1 | 0 | 0
|
197 | INSIGHTS | 1 | 0 | 0
|
198 | INTERFERENCE-MEDIATED | 1 | 0 | 0
|
199 | INTERFERING | 1 | 0 | 2
|
200 | INTERFERON-SENSITIVE | 1 | 0 | 1
|
Page 1 of 2: [ 1 2 ]